Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Sales | 35,691 | 602 | 517 | 504 | 201,206 |
| Gross Profit | 35,691 | 602 | 517 | 504 | 201,206 |
| Operating Expenses | 100,280 | 110,732 | 151,777 | 141,091 | 131,623 |
| Operating Income | -64,589 | -110,130 | -151,260 | -140,587 | 69,583 |
| Other Income | 27,978 | 25,064 | 26,139 | 24,720 | 19,997 |
| Pre-tax Income | -36,611 | -85,066 | -125,121 | -115,867 | 89,580 |
| Income Tax | 700 | 876 | 1,287 | 724 | 233 |
| Net Income Continuous | -37,311 | -85,942 | -126,408 | -116,591 | 89,347 |
| Net Income | $-37,311 | $-85,942 | $-126,408 | $-116,591 | $89,347 |
| EPS Basic Total Ops | -0.41 | -1.01 | -1.49 | -1.43 | 1.12 |
| EPS Basic Continuous Ops | -0.42 | -1.01 | -1.49 | -1.43 | 1.13 |
| EPS Diluted Total Ops | -0.41 | -1.01 | -1.49 | -1.43 | 1.12 |
| EPS Diluted Continuous Ops | -0.42 | -1.01 | -1.49 | -1.43 | 1.13 |
| EPS Diluted Before Non-Recurring Items | -0.44 | -1.01 | -1.49 | N/A | N/A |
| EBITDA(a) | $-59,747 | $-105,391 | $-146,415 | $-135,754 | $74,483 |